SOD1 and amyotrophic lateral sclerosis: Considering the high population frequency of heterozygous SOD1D91A, the debate surrounding its causality and the recent availability of a SOD1-specific drug, there is an urgent need to settle whether ALS patients with a SOD1D91A mutation should be treated with tofersen.